Opiant Pharmaceuticals. found using ticker (OPNT) now have 3 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 44 and 38 calculating the average target price we see 41.33. With the stocks previous close at 8.04 this indicates there is a potential upside of 414.1%. The day 50 moving average is 8.08 and the 200 day MA is 8.45. The market capitalisation for the company is $34m. Visit the company website at: http://www.opiant.com
Opiant Pharmaceuticals., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for opioid overdose; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals. in January 2016. Opiant Pharmaceuticals. was founded in 2005 and is headquartered in Santa Monica, California.